VCA Inc. (WOOF) retreated with the stock falling -0.03% or $-0.03 to close at $90.95 on active trading volume of 3.04M compared its three months average trading volume of 1.62M. The Los Angeles California 90064 based company operating under the Personal Services industry has been trending up for the last 52 weeks, with the shares price now 101.35% up for the period and up by 32.48% so far this year. With price target of $76.01 and a 106.7% rebound from 52-week low, VCA Inc. has plenty of upside potential, making it a hold with a view buy.
VCA Inc. operates as an animal healthcare company in the United States and Canada. It operates in two segments, Animal Hospital and Laboratory. The Animal Hospital segment offers general medical and surgical services for companion animals, as well as specialized treatments comprising diagnostic, internal medicine, oncology, neurology, endocrinology, ophthalmology, dermatology, and cardiology services; and sells related retail and pharmaceutical products. It also provides specialty pet products, including pet food, vitamins, therapeutic shampoos and conditioners, flea collars and sprays, and other accessory products; and additional services, such as grooming, bathing, and boarding services. In addition, this segment performs various pet wellness programs, such as health examinations, diagnostic testing, routine vaccinations, spaying, neutering, and dental care. As of December 31, 2015, it operated or managed 682 animal hospitals. The Laboratory segment offers testing and consulting services used by veterinarians in the detection, diagnosis, evaluation, monitoring, treatment, and prevention of diseases and other conditions affecting animals. This segment serves animal hospitals, animal practices, universities, and other government organizations. It operated a network of 60 laboratories. VCA Inc. also sells digital radiography and ultrasound imaging equipment, related computer hardware, software, and ancillary services to the veterinary market, as well as provides education and training, consulting, and mobile imaging services; and franchises pet services, including dog day care, overnight boarding, grooming, and other ancillary services at pet care facilities. The company was formerly known as VCA Antech, Inc. and changed its name to VCA Inc. in June 2014. VCA Inc. was founded in 1986 and is headquartered in Los Angeles, California.
Celsion Corporation (CLSN) dropped $-0.1 to close the day at a new closing price of $0.41, a -19.41% decrease in value from its previous closing price that moved the stock 41.72% above its 52 week low of $0.29. A total of 3.03M shares exchanged hands during the day compared with its three month average trading volume of 639.00K. The stock, which fluctuated between $0.411 and $0.55 during the day, currently situated -76.91% below its 52 week high. The stock is down by -19.43% in the past one month and down by -62.29% over the past three months. With a one year target estimate of $3.33 and RSI of 45.56, the stock still has upside potential, making it a hold for now.
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The companys lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company also has a collaboration with the Childrens Research Institute to conduct a clinical study of ThermoDox, a heat activated liposomal encapsulation of doxorubicin in combination with magnetic resonance-guided high intensity focused ultrasound to treat relapsed or refractory solid tumors in children and young adults. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
HCP, Inc. (HCP) shares were down in last trading by -0.42% to $30.55. It experienced lighter than average volume on day. The stock increased in value by almost 1.66% over the past week and grew 7.53% in the past month. It is currently trading 3.38% above its 50 day moving average and -3.17% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -16.01% decrease in value from its one year high of $36.82. The RSI indicator value of 55.45, lead us to believe that it is a hold for now.
HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing. The fund also invests in mezzanine loans and other debt instruments. It engages in acquisition, development, leasing, selling and managing of healthcare real estate and provides mortgage and other financing to healthcare providers. The fund benchmarks the performance of its portfolio against the S&P 500 Index, Berkshire Hathaway Index, and MSCI REIT Index. HCP, Inc. was formed in 1985 and is based in Irvine, California with additional office in Nashville and San Francisco.